Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study

Seres Therapeutics Inc MCRB announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate ulcerative colitis (UC). 

  • In July, the Company posted the topline data readout, which noted that the SER-287 Phase 2b study did not achieve its primary endpoints
  • The Company continues to conduct analyses on its SER-287 and SER-301 UC clinical-stage programs to inform next steps for further development.
  • Engraftment of SER-287 bacteria was statistically significant in patients receiving SER-287 versus placebo.
  • The magnitude and kinetics of engraftment were comparable to Seres' Phase 1b study. However, unlike the Phase 1b study, anticipated changes in disease-relevant metabolites post-administration with SER-287 in the Phase 2b study were not observed.
  • "Our SER-287 Phase 2b data suggests that there may be an opportunity to utilize biomarker-based patient selection in our future UC development efforts," said Eric Shaff, Chief Executive Officer at Seres.
  • Price Action: MCRB shares are down 3.55% at $8.42 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 2 Trialulcerative colitis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!